Works by Mark, Tomer M.

Results: 25
    1
    2
    3

    Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.

    Published in:
    American Journal of Hematology, 2021, v. 96, n. 12, p. 1554, doi. 10.1002/ajh.26329
    By:
    • Forsberg, Peter A.;
    • Rossi, Adriana C.;
    • Boyer, Angelique;
    • Pearse, Roger N.;
    • Pekle, Karen A.;
    • Jayabalan, David;
    • Lakritz, Stephanie;
    • Flicker, Kari;
    • Ribadeneyra, Drew;
    • Liotta, Brielle;
    • Ely, Scott;
    • Boussi, Leora;
    • Allan, John N.;
    • Coleman, Morton;
    • Niesvizky, Ruben;
    • Mark, Tomer M.
    Publication type:
    Article
    4

    Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.

    Published in:
    American Journal of Hematology, 2019, v. 94, n. 5, p. 539, doi. 10.1002/ajh.25435
    By:
    • Forsberg, Peter A.;
    • Rossi, Adriana C.;
    • Boyer, Angelique;
    • Tegnestam, Linda;
    • Pearse, Roger N.;
    • Perry, Arthur;
    • Pekle, Karen A.;
    • Jayabalan, David;
    • Ely, Scott;
    • Boussi, Leora;
    • Sherbenou, Daniel W.;
    • Williams, Colt;
    • Allan, John N.;
    • Coleman, Morton;
    • Niesvizky, Ruben;
    • Mark, Tomer M.
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15

    Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.

    Published in:
    2017
    By:
    • Schriber, Jeffrey R.;
    • Hari, Parameswaran N.;
    • Ahn, Kwang Woo;
    • Fei, Mingwei;
    • Costa, Luciano J.;
    • Kharfan‐Dabaja, Mohamad A.;
    • Angel‐Diaz, Miguel;
    • Gale, Robert P.;
    • Ganguly, Siddharatha;
    • Girnius, Saulius K.;
    • Hashmi, Shahrukh;
    • Pawarode, Attaphol;
    • Vesole, David H.;
    • Wiernik, Peter H.;
    • Wirk, Baldeep M.;
    • Marks, David I.;
    • Nishihori, Taiga;
    • Olsson, Richard F.;
    • Usmani, Saad Z.;
    • Mark, Tomer M.
    Publication type:
    journal article
    16
    17
    18

    Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.

    Published in:
    British Journal of Haematology, 2021, v. 193, n. 3, p. 561, doi. 10.1111/bjh.17321
    By:
    • Hungria, Vania;
    • Beksac, Meral;
    • Weisel, Katja C.;
    • Nooka, Ajay K.;
    • Masszi, Tamas;
    • Spicka, Ivan;
    • Munder, Markus;
    • Mateos, María‐Victoria;
    • Mark, Tomer M.;
    • Qi, Ming;
    • Qin, Xiang;
    • Fastenau, John;
    • Spencer, Andrew;
    • Sonneveld, Pieter;
    • Garvin, Wendy;
    • Renaud, Thomas;
    • Gries, Katharine S.
    Publication type:
    Article
    19
    20
    21
    22
    23

    Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.

    Published in:
    Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. N.PAG, doi. 10.1186/s13045-020-00948-5
    By:
    • Weisel, Katja;
    • Spencer, Andrew;
    • Lentzsch, Suzanne;
    • Avet-Loiseau, Hervé;
    • Mark, Tomer M.;
    • Spicka, Ivan;
    • Masszi, Tamas;
    • Lauri, Birgitta;
    • Levin, Mark-David;
    • Bosi, Alberto;
    • Hungria, Vania;
    • Cavo, Michele;
    • Lee, Je-Jung;
    • Nooka, Ajay;
    • Quach, Hang;
    • Munder, Markus;
    • Lee, Cindy;
    • Barreto, Wolney;
    • Corradini, Paolo;
    • Min, Chang-Ki
    Publication type:
    Article
    24
    25